Title: Validation of the new ABC score for predicting 30-day mortality in gastrointestinal
bleeding
Version: 1 Date: 28 Mar 2022
Reviewer's report:
Validation of the new ABC score for predicting 30-day mortality in upper and lower
gastrointestinal bleeding
Thank you for the opportunity to review this study. This manuscript validated the newly
developed scoring system for predicting 30-day mortality of patients who presented with upper-
or lower gastrointestinal bleeding (UGIB or LGIB). However, the authors should be commended
on their work. There are a few areas where additional information would enhance the manuscript.
1. Because the etiologies of GIB are the important factor that contributes to the outcome of
patients with GIB. It is important to reveal the etiologies of GIB in both UGIB and LGIB. And
among patients with UGIB, what is the proportion of portal hypertension-related UGIB (such
as variceal bleeding).
2. As described, 26 (8.4%) patients had GIB of unspecified location. Is it from mid-GIB?
3. The 30-mortality rate of patients with UGIB and LGIB were 16.3% and 10.1%, respectively.
Is it comparable to the previous studies? If not, please provide the reason.
4. What was the cause of mortality, GIB-related, non-GIB related?
5. Because the severity of the disease is another factor that influences the mortality rate, the
author should provide this information. Please provide the mean or median of the prognostic
score according to the location of bleeding (UGIB and LGIB), including AIMS65, Rockall score,
Glasgow-Blatchford score, ABC, Oakland score.
6. The study was conducted between 2013-2020. Did the COVID-19 pandemic occur in your
country at that time? If yes, is its influence on the patients’ outcome.
7. Please recheck the statistical program that the author described in the manuscript. Is it the
same program that the author used in figure generation?
Title: Validation of the new ABC score for predicting 30-day mortality in gastrointestinal
bleeding
Version: 1 Date: 28 Mar 2022
Reviewer's report:
Validation of the new ABC score for predicting 30-day mortality in upper and lower
gastrointestinal bleeding
Thank you for the opportunity to review this study. This manuscript validated the newly
developed scoring system for predicting 30-day mortality of patients who presented with upper-
or lower gastrointestinal bleeding (UGIB or LGIB). However, the authors should be commended
on their work. There are a few areas where additional information would enhance the manuscript.
1. Because the etiologies of GIB are the important factor that contributes to the outcome of
patients with GIB. It is important to reveal the etiologies of GIB in both UGIB and LGIB. And
among patients with UGIB, what is the proportion of portal hypertension-related UGIB (such
as variceal bleeding).
2. As described, 26 (8.4%) patients had GIB of unspecified location. Is it from mid-GIB?
3. The 30-mortality rate of patients with UGIB and LGIB were 16.3% and 10.1%, respectively.
Is it comparable to the previous studies? If not, please provide the reason.
4. What was the cause of mortality, GIB-related, non-GIB related?
5. Because the severity of the disease is another factor that influences the mortality rate, the
author should provide this information. Please provide the mean or median of the prognostic
score according to the location of bleeding (UGIB and LGIB), including AIMS65, Rockall score,
Glasgow-Blatchford score, ABC, Oakland score.
6. The study was conducted between 2013-2020. Did the COVID-19 pandemic occur in your
country at that time? If yes, is its influence on the patients’ outcome.
7. Please recheck the statistical program that the author described in the manuscript. Is it the
same program that the author used in figure generation?
Please review this paper.
user
Title: Validation of the new ABC score for predicting 30-day mortality in gastrointestinal
bleeding
Version: 1 Date: 28 Mar 2022
Reviewer's report:
Validation of the new ABC score for predicting 30-day mortality in upper and lower
gastrointestinal bleeding
Thank you for the opportunity to review this study. This manuscript validated the newly
developed scoring system for predicting 30-day mortality of patients who presented with upper-
or lower gastrointestinal bleeding (UGIB or LGIB). However, the authors should be commended
on their work. There are a few areas where additional information would enhance the manuscript.
1. Because the etiologies of GIB are the important factor that contributes to the outcome of
patients with GIB. It is important to reveal the etiologies of GIB in both UGIB and LGIB. And
among patients with UGIB, what is the proportion of portal hypertension-related UGIB (such
as variceal bleeding).
2. As described, 26 (8.4%) patients had GIB of unspecified location. Is it from mid-GIB?
3. The 30-mortality rate of patients with UGIB and LGIB were 16.3% and 10.1%, respectively.
Is it comparable to the previous studies? If not, please provide the reason.
4. What was the cause of mortality, GIB-related, non-GIB related?
5. Because the severity of the disease is another factor that influences the mortality rate, the
author should provide this information. Please provide the mean or median of the prognostic
score according to the location of bleeding (UGIB and LGIB), including AIMS65, Rockall score,
Glasgow-Blatchford score, ABC, Oakland score.
6. The study was conducted between 2013-2020. Did the COVID-19 pandemic occur in your
country at that time? If yes, is its influence on the patients’ outcome.
7. Please recheck the statistical program that the author described in the manuscript. Is it the
same program that the author used in figure generation?
assistant